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Abstract
Objective To evaluate the safety and effectiveness of chenodeoxycholic acid (CDCA) treatment in patients with
cerebrotendinous xanthomatosis (CTX).
Methods Two retrospective cohort studies were conducted in CTX patients who underwent CDCA treatment: one in the
Netherlands (NL; CDCA-STUK-15-001) and one in Italy (IT; CDCA-STRCH-CR-14-001). Eligible patients were aged 2–75
years, had been diagnosed with CTX, and were treated with CDCA orally for ≥1 year. The impact of CDCA treatment on
biochemical markers (including serum cholestanol levels) and disease signs and symptoms were assessed, in addition to the
safety and tolerability of CDCA treatment.
Results A total of 35 patients were screened in the NL study and were diagnosed with CTX at 25.6 (± 13.7 SD) years on average.
These patients were treated with CDCA and followed up for a median of 9.00 (range: 0.4–26.3) years. In addition, 28 patients
were enrolled in the ITstudy and were diagnosed at 35.0 (± 11.4 SD) years on average (median duration of CDCA treatment: 5.75
[range: 0.0–25.0] years). Signs and symptoms of disease resolved, improved, or remained stable in many patients, with con-
comitant improvements in biochemical marker levels (serum cholestanol, p < 0.001; 7α-hydroxy-4-cholesten-3-one, p < 0.001
[IT study]).
Conclusions The outcomes of these retrospective cohort studies indicate that CDCA is effective in the long-term treatment of
CTX, with an acceptable safety profile.
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Introduction
Cerebrotendinous xanthomatosis (CTX; OMIM 213700) is a
rare, autosomal recessive disorder caused by mutations in
CYP27A1, which lead to a deficiency in sterol 27-
hydroxylase [1, 2]. The latter is important for primary bile
acid synthesis, specifically the conversion of cholesterol to
chenodeoxycholic acid (CDCA) and cholic acid [2, 3]. A de-
ficiency in sterol 27-hydroxylase leads to reduced levels of
CDCA; however, patients may have unaffected or higher
levels of cholic acid [2, 4]. In addition, CTX patients have
high levels of plasma cholestanol, which accumulates in bile
and various tissues, particularly the brain [2].
Manifestations of CTX can vary, not only within families
but even between twins [5]. These include prolonged neonatal
jaundice, infantile-onset chronic diarrhoea, juvenile cataracts,
tendon xanthomas with onset during adolescence or young
adulthood, osteoporosis, and progressive psychiatric and neu-
rological impairment [2, 6]. The latter may include mental
retardation, cerebellar syndrome, pyramidal syndrome, pe-
ripheral neuropathy, epileptic seizures and dementia [2]. The
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accumulation of cholestanol is thought to be responsible for
these neurodegenerative symptoms [2]. Progressive neurolog-
ical and psychiatric dysfunction are the most disabling fea-
tures of CTX [4].
More than 300 patients have been diagnosed with CTX
worldwide, although the condition is likely to be
underdiagnosed [2]. The estimated prevalence of CTX in
white populations is 1:50,000; however, this is limited to pa-
tients with the R362C CYP27A1 mutation [7]. The diagnosis
of CTX typically involves biochemical testing for plasma
cholestanol levels, which in CTX are usually markedly increased
[2]. The normal range for cholestanol is 3.37 ± 1.55 mg/L
(8.66 ± 3.98 μmol/L), but in CTX patients it may be several
times higher than this [8–10]. Elevated plasma concentra-
tion of the bile acid precursor 7α-hydroxy-4-cholesten-3-
one has also been suggested as a new diagnostic marker of
CTX, although these tests are not widely available [8, 11].
Urinary bile alcohol levels can also be used for diagnosis,
although genetic testing for mutations in the CYP27A1
gene is the gold standard and is generally used for confir-
mation of diagnosis [2, 8].
CDCA has become the standard of care for CTX patients
[4]. It prevents the accumulation of cholestanol by inhibiting
bile acid synthesis through a negative feedback pathway [12].
Exogenous CDCA has been shown to improve both biochem-
ical and clinical outcomes in CTX patients [4]. Given the
natural course of CTX, the primary aim of treatment is
stabilisation or improvement of neurological signs and symp-
toms [4]. Nevertheless, a delay in diagnosis and treatment can
lead to a worse prognosis, irreversible neurological damage
and severe disability [13].
A recent study by Stelten et al. (2018) demonstrated that
starting treatment at an early age can reverse and prevent
neurological symptoms [14]. The authors reported results
from a retrospective study performed in the Netherlands
that evaluated the effect of CDCA on disease progression
in 56 CTX patients. Disease progression was measured
through correlation between age at diagnosis and clinical
characteristics, and with the course of modified Rankin
Scale and Expanded Disability Status Scale (EDSS) scores
at follow-up [14].
Here, we present data from two retrospective studies, sub-
mitted for regulatory purposes to the EMA, in CTX patients
who underwent CDCA treatment. The aims of both studies
were to evaluate the impact of CDCA on serum cholestanol
levels (among other biochemical markers), the effectiveness of
this treatment for ameliorating the signs and symptoms of dis-
ease, and the impact on disability scores over time. We also
retrospectively evaluated the safety and tolerability of CDCA
treatment in CTX patients. The results presented herein include
data from 35 patients in the previously described Stelten et al.
(2018) study, conducted in the Netherlands, along with results
from a similar Italian retrospective study [14].
Methods
Data are reported from two retrospective, single-centre, cohort
studies, conducted in the Netherlands (‘NL’; CDCA-STUK-
15-001) and Italy (‘IT’; CDCA-STRCH-CR-14-001).
The NL study
This study was carried out at Canisius-Wilhelmina Hospital in
the Netherlands, an official reference centre for CTX patients.
Eligible patients were aged 2–75 years, with diagnosed
CTX of ≥ 1-year duration that had been treated with CDCA
(750 mg/day or 15 mg/kg/day) orally for ≥ 1 year. This study
used commercially formulated CDCA, which had undergone
production via an industrial process, with quality control per-
formed on every batch.
Patients were required to have ≥ 1 cholestanol and/or uri-
nary bile alcohol assessment ≤ 3 months prior to treatment
with CDCA and ≥ 1 such value within 2 years from the be-
ginning of therapy with CDCA. Demographic and clinical
data were collected prior to CDCA treatment (baseline) and
at two post-treatment visits (V1 and V2). To document the
patient’s current clinical condition (CCC), the most recent
available evaluation was also captured during the CCC visit.
The first patient visit was on 27 November 1981 and the last
on 3 June 2015. Only those patients who were able to attend
hospital visits were included in the analyses presented here.
Baseline characteristics were extracted from medical re-
cords. Effectiveness analyses were conducted in the evaluable
population, which included all eligible patients with (a) ≥ 1
quantitative cholestanol assessment the same day or before
CDCA initiation, and ≥ 1 after initiation, or (b) ≥ 1 qualitative
assessment for urinary bile alcohols the same day or before
CDCA initiation, and ≥ 1 after initiation. Effectiveness vari-
ables included serum cholestanol, urinary bile alcohols and
presence, absence or change in disease signs and symptoms
(including psychiatric, cognitive and neurological impairment,
epilepsy, polyneuropathy and diarrhoea). The latter were deter-
mined through physical examination. Additionally, neurologi-
cal disability scores (Rankin Scale and EDSS) were reported.
Safety variables were collected in the safety population,
which included all eligible patients who had received ≥ 1 dose
of CDCA, regardless of the overall duration of CDCA treat-
ment (i.e. < 1 or ≥ 1 year). Safety variables included adverse
events (AEs; coded using MedDRA 17.0), serious AEs and
laboratory tests.
The IT study
This study was carried out at the Operative Unit of Neurology
and Neurometabolic Disorders, University of Siena, Italy.
Eligible patients were aged 2–75 years, with diagnosed CTX
of ≥ 1-year duration that had been treated with CDCA
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(750 mg/day) orally for ≥ 1 year. Due to limited availability of
commercially produced CDCA prior to licensing, a local
pharmacy-produced galenic formulation of CDCA was used
in this study.
Patients were required to have ≥ 1 cholestanol assessment
and ≥ 1 routine laboratory evaluation ≤ 3 months prior to treat-
ment with CDCA and ≥ 1 of each within 2 years of treatment
initiation. Patients undergoing treatment with other bile acids,
statins or steroids ≤ 3 months before diagnosis, and throughout
the follow-up period, were excluded from the study. As in the
NL study, demographic and clinical data were collected at base-
line, V1, V2 and the CCC visit. The first patient visit was on 3
November 1988 and the last on 22 October 2014.
Baseline characteristics were collected in the screened pop-
ulation by extracting information from medical records.
Effectiveness variables were measured in the evaluable popu-
lation (all patients with ≥ 1 cholestanol assessment prior to,
and ≥ 1 following, CDCA initiation). Effectiveness variables
included serum cholestanol and 7α-hydroxy-4-cholesten-3-
one and presence, absence or change in disease signs and
symptoms (including psychiatric, cognitive and neurological
impairment and diarrhoea). The latter were determined
through physical examination. Additionally, neurological dis-
ability scores (Rankin Scale, EDSS) were reported.
Safety variables were measured as per the NL study.
Statistical analyses (both studies)
Please refer to the Supplemental Material (Online Resource).
Results
The NL study
Patient disposition and baseline characteristics
Thirty-five patients were screened in the study, all of
whom formed the safety population and 31 (88.6%) the
evaluable population (Fig. 1). The majority of patients
were male (n=21; 60.0%), with a mean (± SD) age of
36.6 (± 16.8) years (Table 1). The median time from
baseline visit to V1 was 9.9 months (range: 1.1–186.9),
to V2 was 37.6 months (9.5–252.0), and to the CCC visit
was 120.9 months (26.2–305.3).
Effectiveness
Mean serum cholestanol levels significantly decreased
from baseline to any post-treatment visit (p < 0.001 at
any visit; Fig. 2a). This was consistent between patients
aged < 21 years or ≥ 21 years at treatment initiation
(p < 0.001 at any visit; data not shown).
Neurological impairment was present in 64.5% (20/31)
evaluable patients at baseline, 54.8% (17/31) at V1, 61.3%
(19/31) at V2, and 54.8% (17/31) at the CCC visit.
Psychiatric impairment resolved, improved or stabilised in the
majority of patients with impairment at baseline (n=5/6;
85.7%). Of 31 evaluable patients, cognitive impairment was
present in 58.1% (n=18/31) at baseline. At V1 and V2, there
was improvement or stabilisation in 88.9% (n=16/18) of these
Fig. 1 Patient disposition. Three
patients (10.7%) in the IT study
discontinued, either due to
adverse events (n=1) or
withdrawal of consent (n=2).
Abbreviations: CCC: Current
clinical condition; IT: Italy; NL:
the Netherlands; V1: Post-
treatment visit 1; V2: Post-
treatment visit 2
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patients (data missing for 1 patient), and by the CCC visit,
cognitive symptoms had resolved, stabilised or improved in
all 18 patients with impairment at baseline. Epilepsy resolved,
and polyneuropathy stabilised or improved, in all patients with
these symptoms at baseline (n=3 and 11, respectively). In ad-
dition, diarrhoea had resolved by the CCC visit in all patients
who reported the symptom at the baseline visit (n=23; 100%).
Of the 26 patients with Rankin Scale assessments at both
baseline and the CCC visit, there was an improvement in
15.4% (n=4), stabilisation in 69.2% (n=18) and deterioration in
15.4% (n=4) patients, although there was no difference inmedian
Rankin Scale score frombaseline to theCCCvisit (0.0; range: -1–
2). In addition, the median change from baseline in Rankin Scale
score from baseline to the CCC visit was 0.0 (range: -0.1–0.0)
in patients aged < 21 years at first treatment and 0.0 (range:
0.0–2.0) in patients aged ≥ 21 years at first treatment.
Of the 26 patients with EDSS scores at baseline and the
CCC visit, there was an improvement in 23.1% (n=6),
stabilisation in 53.8% (n=14) and deterioration in 23.1%
(n=6) patients. The median change from baseline in EDSS
score was 0.0 at any post-treatment visit (including when
stratified by age at first treatment).
At baseline, all 29 patients with measurements for urinary
bile alcohols had elevated levels. These decreased or were
normalised in the majority of patients at all post-treatment
visits (Supplemental Table 1, Online Resource). No signifi-
cant difference was observed between the two patient sub-
groups (data not shown).
Safety
The median duration of CDCA treatment in the safety popu-
lation was 9.00 (range: 0.4–26.3) years. A total of 76 AEs
were reported in 26 (74.3%) patients (Table 2), including 9
serious AEs in 7 patients (20.0%), none of which were fatal or
treatment-related. A full listing of AEs and serious AEs can be
found in Supplemental Table 2 (Online Resource). Three pa-
tients had treatment-related AEs (two cases of constipation
and one of toxic hepatitis); none were serious, or of severe
intensity. The hepatitis case was an infant and has previously
Table 1 Baseline demographics and clinical characteristics
NL study
(N = 35)
IT study
(N = 28)
Demographics
Mean age at disease onset, years (± SD) –[a] 11.0 (± 11.2)
Mean age at diagnosis, years (± SD) 25.6 (± 13.7) 35.0 (± 11.4)
Mean age at treatment initiation, years[b]
(± SD)
25.8 (± 14.0) 35.0 (± 11.4)
Mean age at study initiation, years (± SD) 36.6 (± 16.8)
[n = 33][c]
47.4 (± 13.2)
Male, n (%) 21.0 (60.0) 13.0 (46.4)
Clinical characteristics[d]
Mean serum cholestanol levels,
μmol/L (± SD)
76.5 (± 39.0)
[n = 27][e]
87.8 (± 39.2)
Mean 7α-hydroxy-4-cholesten-3-one
level, mmol/L (± SD)
–[f] 9.3 (± 5.7)
[n = 16][g]
Neurological impairment present, n (%) 20 (64.5) 20 (76.9)
Psychiatric impairment present, n (%) 6 (19.4) 13 (50.0)
Cognitive impairment present, n (%) 18 (58.1) 20 (76.9)
Diarrhoea present, n (%) 23 (74.2) 14 (53.8)
Median EDSS score (range) 1.5 (0.0–7.5)
[n = 27][h]
3.5 (0.0–7.0)
Median Rankin scale score (range) 1.0 (0.0–4.0)
[n = 27][h]
2.0 (0.0–4.0)
[a] Data not included due to missing data in 32 patients. [b] In the NL
study, patients were split into subpopulations based on their age at treat-
ment initiation (< 21 or ≥ 21 years). [c] Two patients were deceased when
the NL retrospective study was initiated. [d] The total numbers of patients
are based on the evaluable population in the NL (n=31) and IT (n=26)
studies, unless otherwise stated. [e] Two patients had “elevated” levels
and data were missing for two patients. [f] Data not reported. [g] Data
were missing for 10 patients. [h] Data were missing for four patients.
Abbreviations: EDSS, Expanded Disability Status Scale; IT, Italy; NL,
the Netherlands; SD, standard deviation
Fig. 2 Mean change from baseline in serum cholestanol level (evaluable
populations) (a) NL Study (N=31) (b) IT Study (N=26). Error bars
represent the 95% confidence intervals; ***p < 0.001. The Italian study
originally used values in mg/dL, which have been converted to μmol/L
here. The original mean values (95% CI) for each visit in this study were:
V1, -2.620 mg/dL (-3.313, -1.928); V2, -2.844 mg/dL (-3.324, -2.365);
CCC Visit, -2.683 mg/dL (-3.463, -1.902). Abbreviations: CCC: Current
clinical condition; IT: Italy; NL: the Netherlands; V1: Post-treatment visit
1; V2: Post-treatment visit 2
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been reported byHuidekoper et al. (2016) [15]. Treatment was
suspended and the event considered treatment-related, al-
though hyperbilirubinaemia was present prior to initiation of
treatment. Hepatitis did not recur on re-challenge and ongoing
treatment with CDCA at a lower dose of 5 mg/kg/day.
The IT study
Patient disposition and baseline characteristics
Twenty-eight patients were screened and enrolled in the study,
all of whom were included in the safety analyses and 26
(92.9%) in the effectiveness analyses (Fig. 1). The gender split
was approximately equal (46.4% male), and the mean (± SD)
age of patients was 47.4 (± 13.2) years (Table 1). The median
time from baseline visit to V1 was 23.7 months (range: 5.0–
91.1), to V2 was 52.1 months (17.9–107.1), and to the CCC
visit was 76.1 months (6.4–300.5).
Effectiveness
Mean serum cholestanol levels significantly decreased from
baseline to any post-treatment visit (p < 0.001 at any visit; Fig.
2b). Furthermore, the mean levels of 7α-hydroxy-4-
cholesten-3-one significantly decreased from baseline to V1
and V2 (p < 0.001; Fig. 3).
Neurological impairment was present in 20 patients (76.9%)
at baseline and had stabilised in 9 (45.0%) and deteriorated in
11 (55.0%) of these patients at the CCC visit. Of the 13 patients
who presented with psychiatric impairment at baseline, 92.3%
(n=12) improved or remained stable at the CCC visit. Of 26
evaluable patients, cognitive impairment was present in 20 pa-
tients (76.9%) at baseline and stabilised in 16 (72.7%) patients
at the CCC visit. In addition, diarrhoea stabilised, improved or
disappeared by the CCC visit in the majority of patients who
had this symptom at baseline (n=13/14; 92.8%).
There was no deterioration in Rankin Scale score in
61.5% (n=16/26) patients for the entire follow-up period, and
there was no difference in the median Rankin Scale score from
baseline to the CCC visit (0.0; range: 0–2). Of 26 evaluable
patients, EDSS scores remained stable in 46.1% (n=12/26)
patients, improved in 3.8% (n=1/26) patients and deteriorated
in 50.0% (n=13/26) patients during the study. The median
changes from baseline in EDSS scores were 0.0 at V1 (range:
0.0–2.5) and V2 (range: -0.5–2.0), and 0.5 (range: -0.5–4.0) at
the CCC visit.
Safety
The median duration of treatment in the safety population
was 5.75 (range: 0.0–25.0) years. A total of 16 AEs were
reported in 9 patients (32.1%), including 15 serious AEs
in 9 patients (32.1%; Table 2). The latter included one
fatal case of colon cancer. A full listing of AEs and seri-
ous AEs can be found in Supplemental Table 2 (Online
Resource). Severe AEs were reported in 5 patients
(17.9%), although no patients had treatment-related AEs.
Discussion
CTX is a rare neurometabolic disease that results in neu-
rodegeneration, and for which CDCA treatment is the
standard of care [4]. The two retrospective studies pre-
sented here investigated the safety and effectiveness of
CDCA in two cohorts of patients with confirmed CTX
and ≥ 1 year of exposure to the drug. Across both studies,
CDCA was generally effective and well-tolerated, with
improvement, resolution or stabilisation of the signs and
symptoms of disease in most patients. In addition, there
Fig. 3 Mean change from baseline in 7α-hydroxy-4-cholesten-3-one
level (IT study only; evaluable population). Error bars represent the
95% confidence intervals; ***p < 0.001. The Italian study originally
used values in μg/dL, which have been converted to μmol/L here. The
original mean values (95% CI) for each visit in this study were: V1, -
343.92 μg/dL (-353.27, -334.58); V2, -347.53 μg/dL (-360.08, -334.98).
Abbreviations: IT: Italy; V1: Post-treatment visit 1; V2: Post-treatment
visit 2
Table 2 Summary of adverse events (safety populations)
NL study (N = 35) IT study (N = 28)
n (%) Number
of events
n (%) Number
of events
Any AEs (overall) 26 (74.3) 76 9 (32.1) 16
Mild AEs 23 (65.7) 53 1 (3.6) 1
Moderate AEs 15 (42.9) 22 5 (17.9) 6
Severe AEs 1 (2.9) 1 5 (17.9) 9
Discontinuations due to AEs – – 1 (3.6) 1
Treatment-related AEs 3 (8.6) 3 0 (0.0) 0
Serious AEs 7 (20.0) 9 9 (32.1) 15
Abbreviations: AE, adverse event; IT, Italy; NL, the Netherlands
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was some evidence of improvement or stabilisation in
disability scale scores, although a number of patients also
showed deterioration in these measures. Improvements in
the levels of biochemical markers were evident in both
cohorts, including serum cholestanol, 7α-hydroxy-4-
cholesten-3-one, and/or urinary bile alcohols. These out-
comes reflect those seen in previous studies of CDCA
treatment in patients with CTX [8, 14, 16–18].
Though these observations were broadly comparable be-
tween the two studies, there were some differences. For
instance, while symptoms such as diarrhoea and neurolog-
ical, psychiatric and cognitive impairment frequently im-
proved or resolved in the NL study, they generally remained
stable in the IT study. Differences in age at diagnosis and
treatment initiation may be important reasons for this (pa-
tients in the IT study were older and diagnosed later in life
on average than those in the NL study), although product
differences cannot be ruled out. The observation that mean
serum cholestanol levels significantly declined at each visit,
in both cohorts, demonstrates the comparable effectiveness
of the different formulations and suggests that demographic
variation underlies the apparent differences in treatment ef-
fectiveness. Inter-study differences were also observed in
the Rankin Scale and EDSS scores; this might also be at-
tributable to the older age of patients in the IT study and the
greater severity of their symptoms at baseline. Differences
between the two studies could also have arisen due to as-
sessment and investigator variabilities, such as in the phys-
ical examinations conducted to assess disease signs and
symptoms.
In addition to differences in the clinical outcomes, the
rate of reported AEs was lower in the IT cohort than the
NL cohort. In both studies, AEs were documented and
collected on the basis of source documents available at
the site, and it is not known whether the differences we
report here are real or due to variations in reporting
habits. The NL study also included more AEs unrelated
to CDCA treatment; however, it remains unclear whether
such events were either not reported or not recorded in the
IT study.
Beyond the usual limitations associated with retrospec-
tive data collection (e.g. missing records and the absence
of a control group), a specific limitation of these studies
included the use of raw EDSS scores rather than EDSS
thresholds, which usually range from 0 to 10 in incre-
ments of 0.5. This means that while improvement in
EDSS score was observed for some patients, it is difficult
to discern whether these improvements were clinically
significant across the evaluable population. Nevertheless,
given the chronic and progressive nature of CTX, many
patients already have advanced disease at the time of di-
agnosis, and thus stabilisation of symptoms can be as
important as improvement. An additional limitation of
these studies was the exclusion of patients in the
Netherlands who were institutionalised and therefore un-
able to attend hospital visits. It is not clear to what extent
this might have impacted the observed outcomes.
In summary, the results of these retrospective cohort studies
indicate that CDCA is generally effective at reducing
cholestanol levels and stabilising or improving the progres-
sion of disability and most neurological and non-
neurological manifestations. These studies also demonstrate
that CDCA has an acceptable safety profile in CTX patients
undergoing treatment for a prolonged period of time.
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